272 related articles for article (PubMed ID: 30767432)
1. Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study.
Søgaard M; Nielsen PB; Skjøth F; Kjaeldgaard JN; Larsen TB
Cancer Med; 2019 Mar; 8(3):1044-1053. PubMed ID: 30767432
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.
Sindet-Pedersen C; Staerk L; Pallisgaard JL; Gerds TA; Berger JS; Torp-Pedersen C; Gislason GH; Olesen JB
Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):220-227. PubMed ID: 29945162
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
6. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Nicklaus MD; Ludwig SL; Kettle JK
J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
[TBL] [Abstract][Full Text] [Related]
9. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
[TBL] [Abstract][Full Text] [Related]
10. Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data.
Dawwas GK; Leonard CE; Lewis JD; Cuker A
Ann Intern Med; 2022 Jan; 175(1):20-28. PubMed ID: 34871048
[TBL] [Abstract][Full Text] [Related]
11. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
Streiff MB; Milentijevic D; McCrae K; Yannicelli D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J; Khorana AA
Am J Hematol; 2018 May; 93(5):664-671. PubMed ID: 29396864
[TBL] [Abstract][Full Text] [Related]
13. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry.
Bott-Kitslaar DM; Saadiq RA; McBane RD; Loprinzi CL; Ashrani AA; Ransone TR; Wolfgram AA; Berentsen MM; Wysokinski WE
Am J Med; 2016 Jun; 129(6):615-9. PubMed ID: 26797081
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight.
Wysokinski WE; Froehling DA; Houghton DE; McBane RD; Vlazny DT; Bott-Kitslaar DM; Kuczmik W; Sutkowska K; Bator K; Hodge DO; Peterson LG; Casanegra AI
Eur J Haematol; 2020 Oct; 105(4):484-494. PubMed ID: 32557773
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis.
Kohn CG; Lyman GH; Beyer-Westendorf J; Spyropoulos AC; Bunz TJ; Baker WL; Eriksson D; Meinecke AK; Coleman CI
J Natl Compr Canc Netw; 2018 May; 16(5):491-497. PubMed ID: 29752323
[No Abstract] [Full Text] [Related]
20. Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.
Khorana AA; Berger JS; Wells PS; Seheult R; Ashton V; Laliberté F; Crivera C; Lejeune D; Schein J; Wildgoose P; Lefebvre P; Kaatz S
Clin Ther; 2017 Jul; 39(7):1396-1408. PubMed ID: 28645879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]